Molecular evidence for SARS-CoV-2 in samples collected from patients with morbilliform eruptions since late 2019 in Lombardy, northern Italy.


Journal

Environmental research
ISSN: 1096-0953
Titre abrégé: Environ Res
Pays: Netherlands
ID NLM: 0147621

Informations de publication

Date de publication:
12 2022
Historique:
received: 22 03 2022
revised: 07 07 2022
accepted: 21 07 2022
pubmed: 28 8 2022
medline: 12 10 2022
entrez: 27 8 2022
Statut: ppublish

Résumé

As a reference laboratory for measles and rubella surveillance in Lombardy, we evaluated the association between SARS-CoV-2 infection and measles-like syndromes, providing preliminary evidence for undetected early circulation of SARS-CoV-2. Overall, 435 samples from 156 cases were investigated. RNA from oropharyngeal swabs (N = 148) and urine (N = 141) was screened with four hemi-nested PCRs and molecular evidence for SARS-CoV-2 infection was found in 13 subjects. Two of the positive patients were from the pandemic period (2/12, 16.7%, March 2020-March 2021) and 11 were from the pre-pandemic period (11/44, 25%, August 2019-February 2020). Sera (N = 146) were tested for anti-SARS-CoV-2 IgG, IgM, and IgA antibodies. Five of the RNA-positive individuals also had detectable anti-SARS-CoV-2 antibodies. No strong evidence of infection was found in samples collected between August 2018 and July 2019 from 100 patients. The earliest sample with evidence of SARS-CoV-2 RNA was from September 12, 2019, and the positive patient was also positive for anti-SARS-CoV-2 antibodies (IgG and IgM). Mutations typical of B.1 strains previously reported to have emerged in January 2020 (C3037T, C14408T, and A23403G), were identified in samples collected as early as October 2019 in Lombardy. One of these mutations (C14408T) was also identified among sequences downloaded from public databases that were obtained by others from samples collected in Brazil in November 2019. We conclude that a SARS-CoV-2 progenitor capable of producing a measles-like syndrome may have emerged in late June-late July 2019 and that viruses with mutations characterizing B.1 strain may have been spreading globally before the first Wuhan outbreak. Our findings should be complemented by high-throughput sequencing to obtain additional sequence information. We highlight the importance of retrospective surveillance studies in understanding the early dynamics of COVID-19 spread and we encourage other groups to perform retrospective investigations to seek confirmatory proofs of early SARS-CoV-2 circulation.

Identifiants

pubmed: 36029839
pii: S0013-9351(22)01306-8
doi: 10.1016/j.envres.2022.113979
pmc: PMC9404229
pii:
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin A 0
Immunoglobulin G 0
Immunoglobulin M 0
RNA, Viral 0

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

113979

Subventions

Organisme : NIGMS NIH HHS
ID : R35 GM139540
Pays : United States

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Sci Total Environ. 2022 Feb 1;806(Pt 4):150816
pubmed: 34627901
SN Comput Sci. 2021;2(3):203
pubmed: 33870214
J Clin Med. 2020 Oct 12;9(10):
pubmed: 33053817
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
Emerg Infect Dis. 2021 Feb;27(2):648-650
pubmed: 33292923
Sci Total Environ. 2021 Jan 1;750:141711
pubmed: 32835962
Blood Transfus. 2021 May;19(3):181-189
pubmed: 33539289
J Med Virol. 2022 Mar;94(3):847-857
pubmed: 34609003
PLoS Biol. 2021 Mar 12;19(3):e3001115
pubmed: 33711012
BMJ Glob Health. 2022 Mar;7(3):
pubmed: 35296465
Br J Dermatol. 2021 May;184(5):880-887
pubmed: 33448030
Viruses. 2021 Sep 08;13(9):
pubmed: 34578371
Nature. 2021 Mar;591(7849):188-189
pubmed: 33637873
Viruses. 2021 Dec 30;14(1):
pubmed: 35062265
Clin Infect Dis. 2021 Jun 15;72(12):e1004-e1009
pubmed: 33252659
Mol Biol Evol. 2021 May 19;38(6):2547-2565
pubmed: 33605421
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
Euro Surveill. 2020 Aug;25(31):
pubmed: 32762795
Science. 2020 Oct 30;370(6516):564-570
pubmed: 32912998
J Eur Acad Dermatol Venereol. 2020 May;34(5):e212-e213
pubmed: 32215952
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Nat Commun. 2021 Jan 19;12(1):434
pubmed: 33469026
Lancet Microbe. 2021 Jun;2(6):e240-e249
pubmed: 33778792
J Am Acad Dermatol. 2020 Sep;83(3):965-969
pubmed: 32534082
Travel Med Infect Dis. 2021 Mar-Apr;40:102002
pubmed: 33647467
Infect Drug Resist. 2022 Feb 19;15:533-544
pubmed: 35221698
Mol Biol Evol. 2021 Jul 29;38(8):3046-3059
pubmed: 33942847
Euro Surveill. 2020 Jun;25(24):
pubmed: 32583766
Environ Res. 2021 Oct;201:111542
pubmed: 34153333
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Eur J Epidemiol. 2021 Feb;36(2):219-222
pubmed: 33548003
Int J Antimicrob Agents. 2020 Jun;55(6):106006
pubmed: 32371096
Sci Total Environ. 2021 Jul 15;778:146198
pubmed: 33714813
Br J Dermatol. 2021 May;184(5):970-971
pubmed: 33410129
Science. 2021 Apr 23;372(6540):412-417
pubmed: 33737402
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2499-2504
pubmed: 32585074
Lancet. 2021 Dec 4;398(10316):2109-2124
pubmed: 34762857
Br J Dermatol. 2020 Nov;183(5):866-874
pubmed: 32628270
Lancet Public Health. 2020 Jun;5(6):e310
pubmed: 32339478
Natl Sci Rev. 2021 Dec 11;9(4):nwab223
pubmed: 35497643
Nature. 2021 Apr;592(7854):337-338
pubmed: 33790440
Viruses. 2022 May 17;14(5):
pubmed: 35632809
PLoS Comput Biol. 2020 Jan 17;16(1):e1007046
pubmed: 31951607
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Mol Biol Evol. 2020 Sep 1;37(9):2463-2464
pubmed: 32893295
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Viruses. 2021 Apr 16;13(4):
pubmed: 33923819
J Prev Med Hyg. 2019 Dec 20;60(4):E286-E292
pubmed: 31967085
JAMA. 2020 Apr 28;323(16):1545-1546
pubmed: 32167538
Clin Infect Dis. 2022 Apr 9;74(7):1313-1314
pubmed: 34420046
Br J Dermatol. 2021 Dec;185(6):1176-1185
pubmed: 34611893
Nat Med. 2021 Apr;27(4):717-726
pubmed: 33664494
Front Microbiol. 2022 Jun 15;13:886317
pubmed: 35783409
Tumori. 2021 Oct;107(5):446-451
pubmed: 33176598
Front Public Health. 2020 Nov 23;8:569209
pubmed: 33330316
Mol Biol Evol. 2021 Dec 9;38(12):5211-5224
pubmed: 34398234
Clin Microbiol Infect. 2021 Feb;27(2):289.e5-289.e7
pubmed: 33161149
J Am Acad Dermatol. 2021 Feb;84(2):505-507
pubmed: 32920037
J Am Acad Dermatol. 2021 May;84(5):1356-1363
pubmed: 33476725
PLoS One. 2020 Dec 3;15(12):e0243411
pubmed: 33270782
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Epidemics. 2021 Dec;37:100528
pubmed: 34814093

Auteurs

Antonella Amendola (A)

Department of Health Sciences, University of Milan, 20142, Milan, Italy; Coordinated Research Center "EpiSoMI", University of Milan, 20133, Milan, Italy. Electronic address: antonella.amendola@unimi.it.

Marta Canuti (M)

Department of Health Sciences, University of Milan, 20142, Milan, Italy. Electronic address: marta.canuti@gmail.com.

Silvia Bianchi (S)

Department of Health Sciences, University of Milan, 20142, Milan, Italy; Coordinated Research Center "EpiSoMI", University of Milan, 20133, Milan, Italy. Electronic address: silvia.bianchi@unimi.it.

Sudhir Kumar (S)

Institute for Genomics and Evolutionary Medicine, Temple University, 19122, Philadelphia, USA; Department of Biology, Temple University, 19122, Philadelphia, USA; Center for Excellence in Genome Medicine and Research, King Abdulaziz University, 22252, Jeddah, Saudi Arabia. Electronic address: s.kumar@temple.edu.

Clara Fappani (C)

Department of Health Sciences, University of Milan, 20142, Milan, Italy; Coordinated Research Center "EpiSoMI", University of Milan, 20133, Milan, Italy. Electronic address: clara.fappani@unimi.it.

Maria Gori (M)

Department of Health Sciences, University of Milan, 20142, Milan, Italy; Coordinated Research Center "EpiSoMI", University of Milan, 20133, Milan, Italy. Electronic address: maria.gori@unimi.it.

Daniela Colzani (D)

Department of Health Sciences, University of Milan, 20142, Milan, Italy; Coordinated Research Center "EpiSoMI", University of Milan, 20133, Milan, Italy. Electronic address: daniela.colzani@unimi.it.

Sergei L Kosakovsky Pond (SL)

Institute for Genomics and Evolutionary Medicine, Temple University, 19122, Philadelphia, USA; Department of Biology, Temple University, 19122, Philadelphia, USA. Electronic address: spond@temple.edu.

Sayaka Miura (S)

Institute for Genomics and Evolutionary Medicine, Temple University, 19122, Philadelphia, USA; Department of Biology, Temple University, 19122, Philadelphia, USA. Electronic address: sayaka.miura@temple.edu.

Melissa Baggieri (M)

Department of Infectious Diseases, Istituto Superiore di Sanità, 00161, Rome, Italy. Electronic address: melissa.baggieri@iss.it.

Antonella Marchi (A)

Department of Infectious Diseases, Istituto Superiore di Sanità, 00161, Rome, Italy. Electronic address: antonella.marchi@iss.it.

Elisa Borghi (E)

Department of Health Sciences, University of Milan, 20142, Milan, Italy; Coordinated Research Center "EpiSoMI", University of Milan, 20133, Milan, Italy. Electronic address: elisa.borghi@unimi.it.

Gianvincenzo Zuccotti (G)

Department of Paediatrics, Children Hospital V. Buzzi, University of Milan, 20154, Milan, Italy; Romeo and Enrica Invernizzi Pediatric Research Center, University of Milan, 20154, Milan, Italy. Electronic address: gianvincenzo.zuccotti@unimi.it.

Mario C Raviglione (MC)

Centre for Multidisciplinary Research in Health Science, University of Milan, 20122, Milan, Italy. Electronic address: mario.raviglione@unimi.it.

Fabio Magurano (F)

Department of Infectious Diseases, Istituto Superiore di Sanità, 00161, Rome, Italy. Electronic address: fabio.magurano@iss.it.

Elisabetta Tanzi (E)

Department of Health Sciences, University of Milan, 20142, Milan, Italy; Coordinated Research Center "EpiSoMI", University of Milan, 20133, Milan, Italy. Electronic address: elisabetta.tanzi@unimi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH